MONTREAL, Dec. 03, 2018 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce the appointment of Mr. Jovan Antunovic as Senior Vice President and Chief Commercial Officer.
“Jovan brings the expertise, experience and leadership we were looking for to bring Theratechnologies to the next level. His primary mandate will be to focus on the United States market and to ensure that we fully develop Trogarzo® and EGRIFTA®,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.
“We have found in Jovan a unique blend of large and small pharma marketing and sales experience in North America, Europe and Asia, coupled to a strong understanding of the intricacies of injectable treatments and a deep knowledge of HIV. He will be able to use all these skills in his new position at Theratechnologies,” concluded Mr. Tanguay.
Until October, Mr. Antunovic was Vice President, Specialty/Innovative Medicines Business Lead at Bristol-Myers Squibb Canada. He previously held increasingly senior positions at Abbvie, Abbott and Axcan Pharma.
Mr. Antunovic holds a B.Sc and a M.Sc. in Biochemistry as well as a M.B.A. (Marketing), all from McGill University in Montreal.
About Theratechnologies
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company’s website at www.theratech.com and on SEDAR at www.sedar.com.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them.
Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release.
We refer potential investors to the “Risk Factors” section of our annual information form dated February 6, 2018 for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.
We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
For media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
514-336-7800